Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The State Food and Drug Administration of China (SFDA) has granted a license to Aoxing Pharmaceutical Company's Chinese subsidiary to produce the active pharmaceutical ingredient (API) in Pholcodine, an opioid cough suppressant (antitussive).
Subscribe to our email newsletter
Aoxing is involved in developing, manufacturing, as well as distributing narcotic, pain-management, and addiction treatment pharmaceuticals.
The company said to make the product available in China market and it has also started preparing for the government’s Good Manufacturing Practices (GMP) inspection.
Aoxing Pharmaceutical R&D vice president Guirong Zhou said the receipt of the license is evidence of the quality provided by the company’s research and development team.
"We currently have a number of other products that have completed clinical trials and are in the process of applying for the SFDA production license," Zhou added.
"Our success in obtaining a production license for the Pholcodine API bodes well for success in our future applications."